127 related articles for article (PubMed ID: 1350487)
1. Hemodynamic and metabolic effects of carvedilol: a meta-analysis approach.
Stienen U; Meyer-Sabellek W
Clin Investig; 1992; 70 Suppl 1():S65-72. PubMed ID: 1350487
[TBL] [Abstract][Full Text] [Related]
2. The once-daily dose regimen of carvedilol: a meta-analysis approach.
Stienen U
J Cardiovasc Pharmacol; 1992; 19 Suppl 1():S128-33. PubMed ID: 1378140
[TBL] [Abstract][Full Text] [Related]
3. Antihypertensive effect of carvedilol: a preliminary dose-response study.
Casadei B; Conway J; Coats AJ; Bird R
Clin Investig; 1992; 70 Suppl 1():S37-8. PubMed ID: 1350482
[TBL] [Abstract][Full Text] [Related]
4. Can intravenous beta blockade predict long-term haemodynamic benefit in chronic congestive heart failure secondary to ischaemic heart disease? A comparison between intravenous and oral carvedilol.
DasGupta P; Lahiri A
Clin Investig; 1992; 70 Suppl 1():S98-104. PubMed ID: 1350492
[TBL] [Abstract][Full Text] [Related]
5. Blood pressure lowering efficacy of dual alpha and beta blockers for primary hypertension.
Wong GW; Laugerotte A; Wright JM
Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD007449. PubMed ID: 26306578
[TBL] [Abstract][Full Text] [Related]
6. Carvedilol and atenolol once daily in the treatment of hypertension.
Luurila OJ; Härkönen R; Hilden M; Icen R; Kohvakka A; Linna M; Sillanpää J; Vänskä O; Lukkala K
J Hypertens Suppl; 1989 Dec; 7(6):S264-5. PubMed ID: 2576666
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the hemodynamic effects of metoprolol and carvedilol in hypertensive patients.
Weber K; Bohmeke T; van der Does R; Taylor SH
Cardiovasc Drugs Ther; 1996 May; 10(2):113-7. PubMed ID: 8842502
[TBL] [Abstract][Full Text] [Related]
8. Effect of combining extended-release carvedilol and lisinopril in hypertension: results of the COSMOS study.
Bakris GL; Iyengar M; Lukas MA; Ordronneau P; Weber MA
J Clin Hypertens (Greenwich); 2010 Sep; 12(9):678-86. PubMed ID: 20883227
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of once-daily carvedilol vs twice-daily labetalol in mild to moderate hypertension.
Ollivier JP; Durier P; Bussiere JL; Gayet JL
Eur J Clin Pharmacol; 1990; 38 Suppl 2():S164-6. PubMed ID: 1974509
[TBL] [Abstract][Full Text] [Related]
10. Appropriate dose transition to a controlled-release formulation of carvedilol in patients with hypertension.
Bakris GL; Weber MA
Rev Cardiovasc Med; 2008; 9(2):96-105. PubMed ID: 18660730
[TBL] [Abstract][Full Text] [Related]
11. The effects of 2 beta-receptor blocking agents on the microcirculation of healthy subjects and of hypertensive patients.
Albrecht M; Haustein KO
Int J Clin Pharmacol Ther; 1997 Dec; 35(12):580-6. PubMed ID: 9455718
[TBL] [Abstract][Full Text] [Related]
12. Hemodynamic effects of carvedilol after acute oral administration in hypertensive and normal subjects.
Cournot A; Lim C; Duchier J; Safar M
J Cardiovasc Pharmacol; 1992; 19 Suppl 1():S35-9. PubMed ID: 1378147
[TBL] [Abstract][Full Text] [Related]
13. Carvedilol in hypertension: effects on hemodynamics and 24-hour blood pressure.
Lund-Johansen P; Omvik P; Nordrehaug JE; White W
J Cardiovasc Pharmacol; 1992; 19 Suppl 1():S27-34. PubMed ID: 1378146
[TBL] [Abstract][Full Text] [Related]
14. Can intravenous beta-blockade predict long-term hemodynamic benefit in chronic congestive heart failure secondary to ischemic heart disease? A comparison of intravenous with oral carvedilol.
DasGupta P; Lahiri A
J Cardiovasc Pharmacol; 1992; 19 Suppl 1():S62-7. PubMed ID: 1378153
[TBL] [Abstract][Full Text] [Related]
15. Acute and chronic haemodynamic and renal effects of carvedilol in patients with cirrhosis.
Stanley AJ; Therapondos G; Helmy A; Hayes PC
J Hepatol; 1999 Mar; 30(3):479-84. PubMed ID: 10190732
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of carvedilol in renal hypertension. A multicenter open trial.
Takeda T; Kohno M; Ishii M; Kubo S; Saruta T; Mizuno Y; Fukiyama K; Fujishima M; Yoshimura M
Eur J Clin Pharmacol; 1990; 38 Suppl 2():S158-63. PubMed ID: 1974508
[TBL] [Abstract][Full Text] [Related]
17. Alpha 1-blocking properties of carvedilol during acute and chronic administration.
Giannattasio C; Cattaneo BM; Seravalle G; Carugo S; Mangoni AA; Grassi G; Zanchetti A; Mancia G
J Cardiovasc Pharmacol; 1992; 19 Suppl 1():S18-22. PubMed ID: 1378144
[TBL] [Abstract][Full Text] [Related]
18. Haemodynamic effects of acute and chronic administration of low-dose carvedilol, a vasodilating beta-blocker, in patients with cirrhosis and portal hypertension.
Tripathi D; Therapondos G; Lui HF; Stanley AJ; Hayes PC
Aliment Pharmacol Ther; 2002 Mar; 16(3):373-80. PubMed ID: 11876689
[TBL] [Abstract][Full Text] [Related]
19. The effect of low dose carvedilol on circadian variation of blood pressure in patients with essential hypertension.
Ogihara T; Ikeda M; Goto Y; Yoshinaga K; Kumahara Y; Iimura O; Ishii M; Murakami E; Takeda T; Kokubu T
J Cardiovasc Pharmacol; 1987; 10 Suppl 11():S108-12. PubMed ID: 2454355
[TBL] [Abstract][Full Text] [Related]
20. Chronic haemodynamic effects of carvedilol in essential hypertension at rest and during exercise.
Lund-Johansen P; Omvik P
Eur Heart J; 1992 Feb; 13(2):281-6. PubMed ID: 1555629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
